Prostacyclin treatment and clinical outcome in severe traumatic brain injury patients managed with an ICP-targeted therapy: A prospective study

Abstract

Objective: To prospectively assess clinical outcome in patients with severe traumatic brain injury (sTBI) managed according to an ICP-targeted programme as well as additional treatment with prostacyclin.

Materials and methods: Inclusion criteria were GCS ≤8, age 15–70 years, first recorded cerebral perfusion pressure (CPP) > 10 mm Hg. Exclusion criteria were pregnancy, breastfeeding or penetrating brain injury. The patients were treated using the same ICP-guided protocol, with one group randomized to receive prostacyclin in a low dose (0.5 ng kg⁻¹min⁻¹). The clinical outcome was prospectively assessed at 3, 6, 12, 18 and 24 months using structured interviews.

Results: Forty-eight patients were included, mean age 35.5 years, median GCS 6 (3–8), 69% were multi-traumatized. Mortality at 3 months was 12.5%. Median Glasgow Outcome Scale (GOS) at all follow-up points was 4. Favourable outcome (GOS 4–5) at 3 months was 52%, at 24 months 64%. Favourable outcome increased over time. There was a statistically significant association between GOS, GCS at admission and age. Higher ICP_max was associated with worse outcome.

Conclusion: With this treatment protocol, a low number of deaths and a high number of favourable outcomes in sTBI were observed. Prostacyclin in this low dose does not seem to improve the outcome. ICP_max is a positive predictor of worse outcome. Higher GCS at admission and lower age are correlated to better outcome.

• Outcome
• long-time
• severe traumatic brain injury
• ICP
• prostacyclin